Manifestações dermatológicas em uma casuística de doença hepática crônica de um hospital de referência em Belém, Estado do Pará, Brasil

Preclinical Study of Morinda Citrifolia Linn Concentration and Usage Time and its Liver and Renal Toxicity

“…In addition, the metabolism of proteins, carbohydrates, fat and drugs occurs in the liver, making this organ vulnerable to diseases. The use of medicinal plants for health promotion and as therapeutic target has caused hepatic diseases and increased number of steatosis cases [13] . During data collection, it was observed skin lesion caused for cutaneous pruritus in the animals of group treated with 50% Noni for 90 days.…”

“…These alterations may be related to the rising of transaminases and to the risk of liver disease or possible hepatic damage caused by Morinda C. Linn administration. According to Maia (2014) [13] , liver disease may be associated with several extrahepatic signs such as in the renal and nervous systems, gastrointestinal tract and skin. Cutaneous changes may represent the first sign of disease hepatic risk or impairment since 91.4% of patients with hepatic disease develop cutaneous manifestations [13] .…”

“…According to Maia (2014) [13] , liver disease may be associated with several extrahepatic signs such as in the renal and nervous systems, gastrointestinal tract and skin. Cutaneous changes may represent the first sign of disease hepatic risk or impairment since 91.4% of patients with hepatic disease develop cutaneous manifestations [13] . Unlike our results and other study [9] , Serafini and collaborators (2011) [14] showed that doses of 620 mg ingested by Wistar rats, twice a day, 1000 mg/day or 30 ml/day can be considered safe because they are not lethal and do not cause cytotoxicity.…”